Title: Daclizumab
CAS Registry Number: 152923-56-3
CAS Name: Anti-(human interleukin 2 receptor) immunoglobulin G1 (human-mouse monoclonal clone 1H4 g1-chain) disulfide with human-mouse monoclonal clone 1H4 light chain, dimer
Additional Names: humanized anti-Tac; HAT; dacliximab
Manufacturers' Codes: Ro-24-7375
Trademarks: Zenapax (Roche)
Literature References: Humanized monoclonal antibody directed against the a-subunit (p55 alpha, CD25, or Tac subunit) of the human interleukin-2 receptor (IL-2Ra) that is expressed on the surface of activated T lymphocytes. Glycoprotein, mol wt ~150 kDa. DNA sequence is ~90% human origin and ~10% mouse origin. Prepn: C. Queen et al., Proc. Natl. Acad. Sci. USA 86, 10029 (1989). See also: C. L. Queen, H. E. Selick, US 5530101 (1996 to Protein Design Labs). ELISA determn in serum: B. E. Fayer et al., J. Immunol. Methods 186, 47 (1995). Clinical trial in renal transplantation: B. Nashan et al., Transplantation 67, 110 (1999); in cardiac transplantation: A. Beniaminovitz et al., N. Engl. J. Med. 342, 613 (2000). Review of development: J. Hakimi et al. in Antibody Therapeutics, W. J. Harris, J. R. Adair, Eds. (CRC Press, Boca Raton, 1997) pp 277-300; of clinical efficacy in solid organ transplantation: A. M. Wiland, B. Philosophe, Expert Opin. Biol. Ther. 4, 729-740 (2004).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.
Dactinomycin Dalapon Dalbavancin Dalfopristin D-Allose

Daclizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD25
Clinical data
Trade names Zenapax
AHFS/Drugs.com monograph
Pregnancy cat. C
Legal status -only (US) European marketing authorisation withdrawn
Routes Intravenous
Pharmacokinetic data
Half-life 20 days (11–38 days)
CAS number 152923-56-3 YesY
ATC code L04AC01
DrugBank DB00111
Chemical data
Formula C6332H9808N1678O1989S42 
Mol. mass 142,612.1 g/mol
 N (what is this?)  (verify)

Daclizumab (trade name Zenapax) is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis.

Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells. The drug is marketed in the US, but not in Europe.